zm 336372 has been researched along with Arthritis, Rheumatoid in 1 studies
N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, DS | 1 |
| Belfield, AJ | 1 |
| Brown, GR | 1 |
| Campbell, D | 1 |
| Foubister, A | 1 |
| Masters, DJ | 1 |
| Pike, KG | 1 |
| Snelson, WL | 1 |
| Wells, SL | 1 |
1 other study available for zm 336372 and Arthritis, Rheumatoid
| Article | Year |
|---|---|
A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Topics: Amides; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; In Vitro Techniques; Leukocyte | 2004 |